Sepragen

Executive Summary

Sepragen Corporation is a US-based biotechnology company specializing in radial flow chromatography systems and columns for the purification of biologics, vaccines, and diagnostics. Founded in 1988, the company's innovative technology provides high-throughput, automated, and compact solutions that reduce costs and accelerate drug development. Sepragen's equipment is used in the manufacturing of over 24 FDA-approved drugs, demonstrating its established role in the bioprocessing industry. The company focuses on addressing the growing demand for efficient purification processes, particularly for emerging modalities such as cell and gene therapies. With its patented radial flow chromatography, Sepragen offers a unique value proposition in terms of speed, scalability, and reduced buffer consumption, making it an attractive partner for biopharmaceutical manufacturers.

Upcoming Catalysts (preview)

• Q4 2026Launch of Next-Gen Radial Flow Chromatography System for Gene Therapy60% success
• Q2 2027Strategic Partnership with Leading CDMO for Technology Integration50% success
• TBDExpansion into Asian Markets via Distribution Agreement40% success